---

---

tags : Phase 2    entities : Athira pharma, inc.   

save search

---

Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Published: 2022-11-21 (Crawled : 13:20) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K |

Health Technology

| -36.02% | O: -0.31% H: 1.56% C: -0.31%
pharma trials conference disease biomarker alzheimer’s study fosgonimeton phase 2

---

Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
Published: 2022-10-17 (Crawled : 12:00) - biospace.com/
ATHA | $2.12 2.91% 2.83% 200K |

Health Technology

| -35.83% | O: 2.49% H: 10.94% C: 6.38%
pharma alzheimer’s study fosgonimeton phase 2

---

Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Published: 2022-06-22 (Crawled : 12:00) - biospace.com/
ATHA | $2.12 2.91% 2.83% 200K |

Health Technology

| -76.4% | O: -69.76% H: 17.42% C: 7.95%
pharma disease topline alzheimer’s results act-ad phase 2 ath-1017 alzheimer's fosgonimeton phase 2

---

Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress
Published: 2022-03-20 (Crawled : 12:20) - globenewswire.com
ATHA | $2.12 2.91% 2.83% 200K |

Health Technology

| Email alert Add to watchlist
alzheimer phase 2 trial disease alzheimer’s alzheimer's disease alzheimer's act-ad phase 2 fosgonimeton

---

Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 Congress
Published: 2022-03-14 (Crawled : 14:30) - biospace.com/
ATHA | $2.12 2.91% 2.83% 200K |

Health Technology

| -78.67% | O: -1.35% H: 3.46% C: 0.0%
ath-1017 alzheimer phase 2 trial disease alzheimer’s alzheimer's disease alzheimer's act-ad phase 2 fosgonimeton

---

Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease
Published: 2022-02-22 (Crawled : 20:00) - biospace.com/
ATHA | $2.12 2.91% 2.83% 200K |

Health Technology

| -77.87% | O: -1.18% H: 3.04% C: 0.54%
ath-1017 alzheimer disease phase 1 phase 2 alzheimer’s alzheimer's disease alzheimer's fosgonimeton

---

Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
Published: 2022-01-25 (Crawled : 13:30) - biospace.com/
ATHA | $2.12 2.91% 2.83% 200K |

Health Technology

| -81.17% | O: -10.1% H: 13.42% C: 9.61%
ath-1017 treatment phase 2 dementia parkinson trial disease

---

Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease
Published: 2021-10-22 (Crawled : 12:00) - athira.com
ATHA | $2.12 2.91% 2.83% 200K |

Health Technology

| -78.61% | O: 9.45% H: 9.46% C: 1.61%
disease alzheimer phase 2 ath-1017 trial enroll alzheimer’s alzheimer's disease alzheimer's

---

Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Published: 2021-09-29 (Crawled : 11:00) - athira.com
ATHA | $2.12 2.91% 2.83% 200K |

Health Technology

| -77.85% | O: 0.75% H: 1.17% C: -0.75%
disease alzheimer phase 2 ath-1017 clinical trials phase 2/3 trials trial conference alzheimer’s alzheimer's disease alzheimer's

---

Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association International Conference 2021 (AAIC)
Published: 2021-07-19 (Crawled : 11:00) - athira.com
ATHA | $2.12 2.91% 2.83% 200K |

Health Technology

| -79.34% | O: -7.12% H: 9.29% C: 7.56%
alzheimer phase 1 conference ath-1017 phase 2 phase 3 alzheimer’s alzheimer's

---

Gainers vs Losers

67%

33%

Top 10 Gainers

AGBA | News | $1.26 215.0% 68.25% 130M |

Finance

EGOX | $0.0515 43.06% 30.1% 330M |

OLB 4 | $0.33 -14.95% 25.53% 840K |

Technology Services

NVFY | $2.77 31.28% 23.83% 33M |

Consumer Durables

ZCMD | $1.87 28.97% 22.46% 31M |

Commercial Services

RCON | $0.1112 13.01% 21.28% 1.7M |

Distribution Services

INSG | $3.03 25.21% 20.13% 330K |

Electronic Technology

GCTK | $0.8191 22.25% 18.2% 190K |

Manufacturing

WLGS | News | $0.59 18.0% 17.9% 2.3M |

ASNS | $0.828 21.75% 17.86% 18K |

---

Your saved searches

---